These toxicant-responsive modules sit within a BLCA landscape already enriched for targetable oncogenic circuitry: Pan-cancer efforts highlight frequent RTK–RAS/MAPK pathway alterations across tumors, and bladder-focused studies identify RAS-/RAF-driven subsets and MAPK activation linked to aggressive disease behavior [56]. Here, RAF1 is linked to cancer.